Hepatic Involvement of Diffuse Large B-Cell Lymphoma Mimicking Antinuclear Antibody-Negative Autoimmune Hepatitis Diagnosed by Liver Biopsy.
Euna LeeMin-Kyu KangGabin MoonMi-Jin GuPublished in: Medicina (Kaunas, Lithuania) (2022)
Non-Hodgkin's lymphoma (NHL) is the fifth most common hematologic disorder in the United States, and its prevalence has been rising in Western countries. Among the subtypes of NHL, diffuse large B-cell lymphoma (DLBCL) mostly involves the lymph nodes, stomach, and gastrointestinal tract, whereas hepatic involvement of DLBCL is rare. On serologic testing, elevated immunoglobulin G (IgG) levels can be observed in DLBCL; however, elevated IgG levels are mainly observed in autoimmune hepatitis. A targeted-lesion biopsy is required for the diagnosis of DLBCL. Based on a final diagnosis, the patient was treated with rituximab-based chemotherapy, including cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (R-CHOP). Herein, we report a case of DLBCL mimicking antinuclear antibody-negative autoimmune hepatitis, which was finally diagnosed as DLBCL involving the liver, and was confirmed by liver biopsy.
Keyphrases
- diffuse large b cell lymphoma
- epstein barr virus
- lymph node
- multiple sclerosis
- ultrasound guided
- fine needle aspiration
- cancer therapy
- locally advanced
- low dose
- drug delivery
- drug induced
- risk factors
- high dose
- radiation therapy
- sars cov
- respiratory syndrome coronavirus
- newly diagnosed
- sentinel lymph node
- rectal cancer